cfi-402257
Small moleculeexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02792465)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dual specificity protein kinase TTKINHIBITOR
TTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cfi-402257
- cfi-402257
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05251714 | Phase 1/Phase 2 (Phase 2) | May 27, 2022 | Ohio State University, Treadwell Therapeutics, Inc |
| NCT03568422 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Canadian Breast Cancer Foundation, Canadian Cancer Trials Group, Ontario Institute for Cancer Research, Queen's University, Belfast, Stand Up To Cancer, University of Toronto |
| NCT02792465 | Phase 1 | Jul 1, 2016 | University of Toronto |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Toronto | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Canadian Breast Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Ontario Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Queen's University, Belfast | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Treadwell Therapeutics, Inc | For profit | 1 | 1 | 1 | 2022 |
8 organizations
Page 1 / 1